Joseph A Odin, MD, PhD
- ASSOCIATE PROFESSOR | Medicine, Liver Diseases
Specialties:Liver Medicine, Liver Transplantation
Dr. Odin is an associate professor in the Division of Liver Diseases and the Recanati/Miller Transplantation Institute with a clinical background in gastroenterology and liver disease. He is co-director of the Mount Sinai Autoimmune Liver Disease Program. He has research interest in liver autoimmunity and toxicology. His current research studies are focused on novel treatments for primary biliary cirrhosis, primary sclerosing cholangitis and the effect of drugs and toxins on the liver. He cares for individuals with all liver diseases including those with liver transplants. His research is supported by the NIH and he has received past support and awards from the American Gastroenterolofical Association and the American Association for the Study of Liver Disease. He also receives support from pharmaceutical companies for participation in clinical trials examining treatments for viral hepatitis.
Dr. Odin was recently designated as a Fellow of the American Association for the Study of Liver Diseases (FAASLD) — the highest honor among AASLD membership categories — which recognizes superior professional achievement in clinical or academic practice, and in basic or clinical research.
RMTI Website: www.MountSinaiRMTI.org
Autoimmune Liver Disease Treatment Program
- Endoscopic Band Ligation
- Esophageal Varices
- Hepatitis A
- Hepatitis B
AB, Cornell University
MD, Mount Sinai Sch. of Medicine CUNY
Residency, Internal Medicine, Mount Sinai Hospital
Fellowship, Gastroenterology, Johns Hopkins Hospital
Solomon Silver Award for Clinical Research
Research Excellence in GI and Liver Disease Award
Dr. Odin's liver research focuses on Autoimmune Liver Disease, Toxicity, Fatty Liver Disease, and Viral Hepatitis. Clinical trials and studies are being conducted or planned for primary biliary cirrhosis, primary sclerosing cholangitis, autoimmune hepatitis, drug or toxin induced liver injury, hepatitis B and C, and non-alcoholic fatty liver disease. Some of the research is investigator initiated while other studies are supported by the National Institutes of Health or Pharmaceutical Companies. Please go to Programs in Autoimmune Liver Diseases.
- A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for 12 Weeks in Patients with Primary Sclerosing Cholangitis (PSC)
The purpose of this study is to determine if an investigational drug, NGM282, is safe and effective in the treatment of Primary Sclerosing Cholangitis (PSC), compared with the standard treatment. PSC is a long term liver disease that slowly damages the bile ducts, or tubes.
Hirschfield GM, Liu X, Han Y, Gorlov IP, Lu Y, Xu C, Lu Y, Chen W, Juran BD, Coltescu C, Mason AL, Milkiewicz P, Myers RP, Odin JA, Luketic VA, Speiciene D, Vincent C, Levy C, Gregersen PK, Zhang J, Heathcote EJ, Lazaridis KN, Amos CI, Siminovitch KA. Variants at IRF5-TNPO3, 17q12-21 and MMEL1 are associated with primary biliary cirrhosis. Nature genetics 2010 Aug; 42(8).
Singal AK, Stanca CM, Clark V, Dixon L, Levy C, Odin JA, Fiel MI, Friedman SL, Bach N. Natural history of small duct primary sclerosing cholangitis: a case series with review of the literature. Hepatology international 2011 Sep; 5(3).
Allina J, Grabowski J, Doherty-Lyons S, Fiel MI, Jackson CE, Zelikoff JT, Odin JA. Maternal allergy acts synergistically with cigarette smoke exposure during pregnancy to induce hepatic fibrosis in adult male offspring. Journal of immunotoxicology; 8(4).
Hirschfield GM, Xie G, Lu E, Sun Y, Juran BD, Chellappa V, Coltescu C, Mason AL, Milkiewicz P, Myers RP, Odin JA, Luketic VA, Bacon B, Bodenheimer H, Liakina V, Vincent C, Levy C, Pillai S, Lazaridis KN, Amos CI, Siminovitch KA. Association of primary biliary cirrhosis with variants in the CLEC16A, SOCS1, SPIB and SIAE immunomodulatory genes. Genes and immunity 2012 Jun; 13(4).
Hu B, Allina J, Bai J, Kesar V, Odin JA. Catalase and estradiol inhibit mitochondrial protein S-glutathionylation. Molecular and cellular biochemistry 2012 Aug; 367(1-2).
Juran BD, Hirschfield GM, Invernizzi P, Atkinson EJ, Li Y, Xie G, Kosoy R, Ransom M, Sun Y, Bianchi I, Schlicht EM, Lleo A, Coltescu C, Bernuzzi F, Podda M, Lammert C, Shigeta R, Chan LL, Balschun T, Marconi M, Cusi D, Heathcote EJ, Mason AL, Myers RP, Milkiewicz P, Odin JA, Luketic VA, Bacon BR, Bodenheimer HC, Liakina V, Vincent C, Levy C, Franke A, Gregersen PK, Bossa F, Gershwin ME, deAndrade M, Amos CI, Lazaridis KN, Seldin MF, Siminovitch KA. Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants. Human molecular genetics 2012 Dec; 21(23).
Torres J, Bao X, Iuga AC, Chen A, Harpaz N, Ullman T, Cohen BL, Pineton de Chambrun G, Asciutti S, Odin JA, Sachar DB, Gaskins HR, Setchell K, Colombel JF, Itzkowitz SH. Farnesoid X receptor expression is decreased in colonic mucosa of patients with primary sclerosing cholangitis and colitis-associated neoplasia. Inflammatory bowel diseases 2013 Feb; 19(2).